What's the SCORE with triamcinolone?

Article

Triamcinolone acetonide injections for macular oedema associated with retinal vein occlusion have become a therapeutic mainstay, but conflicting data has emerged about the safety of these injections, and some reports indicate that visual stabilization rather than visual improvement is occurring, according to research presented at the 2006 meeting of the AAO in Las Vegas.

Triamcinolone acetonide injections for macular oedema associated with retinal vein occlusion have become a therapeutic mainstay, but conflicting data has emerged about the safety of these injections, and some reports indicate that visual stabilization rather than visual improvement is occurring, according to research presented at the 2006 meeting of the AAO in Las Vegas.

The Standard Care versus Corticosteroid for Retinal Vein Occlusion (SCORE) study has been launched to provide long-term data on the safety and efficacy of this treatment approach, and more than 400 patients have now been enrolled at 82 clinical sites, according to Ingrid U. Scott, MD, MPH, professor of ophthalmology and health evaluation science, Penn State College of Medicine, USA.

"This is expected to be a definitive trial on the role of intravitreal triamcinolone for macular oedema associated with retinal vein occlusion with a one year primary outcome assessment," Dr Scott remarked.

SCORE is a randomized, controlled, multicentre Phase III trial that began in 2003 and is funded by the National Eye Institute. Separate trials are being conducted under the SCORE umbrella for central retinal vein occlusion and for branch retinal vein occlusion. In both trials, patients are randomized 1:1:1 to 1 mg of steroid, 4 mg of steroid, or standard care.

"The SCORE study is a collaborative effort among ophthalmologists in both private practice and academia, the National Eye Institute, regulatory agencies, and an industry partner. This study provides us the opportunity to find an effective treatment for patients with central retinal vein occlusion and a more effective treatment for branch retinal vein occlusion," Dr Scott said.

Intravitreal corticosteroid injections for macular oedema associated with retinal vein occlusion were introduced in 1999, and initial reports appeared promising, with dramatic improvements in macular oedema and visual acuity in some patients to a level that had not been previously reported, Dr. Scott said. This therapeutic intervention was widely adopted, but the relative lack of long-term follow-up data and new questions about safety and effectiveness prompted the design of the SCORE study.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
3 experts are featured in this series.
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
3 experts are featured in this series.
© 2025 MJH Life Sciences

All rights reserved.